ClearPoint Neuro Missed Consensus Estimates

ClearPoint Neuro (CLPT) reported a loss of $0.38 per share on revenue of $10.88 million for the second quarter ended June 2026. The consensus estimate was a loss of $0.29 per share on revenue of $13.00 million. The company missed consensus estimates by 31.03% while revenue grew 18.07% on a year-over-year basis.

ClearPoint Neuro’s mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy.